The FDA has approved a new drug called zolbetuximab designed to attack a novel target that’s in a type of stomach cancer.

Vyloy is the first CLDN18.2-targeting drug to reach the US market but has already been approved in Japan as well as in the EU ...

Claudin 18.2 testing is a crucial step in determining whether Vyloy will be an effective treatment option for you patients with advanced gastric cancer.

In Germany, around 17,000 people are diagnosed with gastric cancer every year. The disease is one of the leading causes of ...

U.S. Food and Drug Administration (FDA) has approved VYLOY™ (zolbetuximab-clzb) in combination with fluoropyrimidine- and ...

FDA also approved the Ventana CLDN18 (43-14A) RxDx Assay, from Ventana Medical Systems, Inc. and Roche Diagnostics, to ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA approved zolbetuximab (Vyloy), a claudin 18.2 (CLDN18.2)-directed cytolytic antibody, in combination with ...

The FDA has approved Vyloy (zolbetuximab-clzb) in combination with chemotherapy to treat advanced gastric or GEJ cancer.

In Germany, around 17,000 people are diagnosed with gastric cancer every year. The disease is one of the leading causes of ...

The primary endpoint is progression-free survival (PFS) in participants treated with the combination of zolbetuximab plus mFOLFOX6 compared to those treated with placebo plus mFOLFOX6. Secondary ...

Thanks to the recently published data, zolbetuximab has now been approved as a drug in Europe. Patients with gastric cancer are expected to be able to be treated with it in Germany from the end of ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved VYLOY™ (zolbetuximab-clzb) in combination ...